Aim: To study the role of CDH1/E-cadherin (E-cad) gene alteration profiles including mutation, loss of heterozygosity (LOH), promoter polymorphism and hypermethylation in mechanisms of CDH1 inactivation in gastric carcinoma (GC).

Methods: Specimens were collected surgically from 70 patients with GC. Allelotyping PCR and detection of LOH, denaturing high pressure liquid chromatography and DNA sequencing, restriction fragment length polymorphism analysis, methylation specific PCR, and immunohistochemical staining were used.

Results: Promoter polymorphism was not a major mechanism of E-cad inactivation. Only one truncating mutation was found in a diffuse type tumor (3%). Both LOH and promoter hypermethylation were major mechanisms of E-cad inactivation, but interestingly, there was a negative association between the fraction of allelic loss (LOH) in tumors and hypermethylation of CDH1. Therefore LOH and hypermethylation were two different tumorigenic pathways involved in GC.

Conclusion: Given the findings that somatic mutation was extremely low and the relationship between LOH and hypermethylation was inverse, any two combinations of these three factors cannot fulfill the classical two-hit hypothesis of CDH1 inactivation. Thus, other mechanisms operating at the transcriptional level or at the post-translational level might be required to induce E-cadherin inactivation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087641PMC
http://dx.doi.org/10.3748/wjg.v12.i14.2168DOI Listing

Publication Analysis

Top Keywords

loh promoter
8
promoter polymorphism
8
cdh1 inactivation
8
e-cad inactivation
8
loh hypermethylation
8
loh
6
hypermethylation
5
inactivation
5
mechanisms
4
mechanisms inactivating
4

Similar Publications

Article Synopsis
  • Hepatocellular carcinoma (HCC) has metabolic abnormalities that help cancer cells grow and resist treatment, making it vital to study new metabolic factors linked to these issues for better understanding and potential therapy advancements.
  • An analysis of cancer data revealed that a particular gene module correlates with advanced HCC disease and the maintenance of cancer stem cells, leading to the identification of 361 deregulated genes, with diacylglycerol kinase eta (DGKH) being a key player in promoting aggressive cancer traits.
  • DGKH's elevated levels in tumors make patients less responsive to treatments, and its action involves enhancing mTOR signaling through phosphatidic acid production; targeting DGKH may improve treatment outcomes
View Article and Find Full Text PDF

In ovarian and breast cancer, promoter methylation of or is a promising biomarker for PARP inhibitor response, as high levels lead to homologous recombination deficiency (HRD). Yet the extent and role of such methylation in other cancers is not clear. This study comprehensively investigated promoter methylation of eight homologous recombination repair genes across 23 solid cancer types.

View Article and Find Full Text PDF

DNA methylation differences between the female and male X chromosomes in human brain.

bioRxiv

April 2024

Department of Ecology and Evolution and Marine Biology, Department of Molecular, Cellular and Developmental Biology, Neuroscience Research Institute, University of California, Santa Barbara.

The mechanisms of X chromosome inactivation suggest fundamental epigenetic differences between the female and male X chromosomes. However, DNA methylation studies often exclude the X chromosomes. In addition, many previous studies relied on techniques that examine non-randomly selected subsets of positions such as array-based methods, rather than assessing the whole X chromosome.

View Article and Find Full Text PDF

Since the World Health Organization (WHO) 2016 revision, the number of molecular markers required for diffuse gliomas has increased, placing a burden on clinical practice. We have established an in-house, molecular diagnostic platform using Senshin-Iryo, a feature of Japan's unique healthcare system, and partially modified the analysis method in accordance with the WHO 2021 revision. Herein, we review over a total 5 years of achievements using this platform.

View Article and Find Full Text PDF

Exercise and inflammatory cytokine regulation among older adults with myeloid malignancies.

Exp Gerontol

March 2024

James P. Wilmot Cancer Institute, Rochester, NY, USA; Division of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA. Electronic address:

Tumor necrosis factor (TNF)α is a major regulator of inflammation. However, the epigenetic regulation of TNFα in the context of an exercise intervention among older adults with cancer is understudied. In this exploratory analysis, we used data from a single-arm mobile health (mHealth) exercise intervention among older adults with myeloid malignancies to 1) assess changes in TNFα promoter methylation, TNFα mRNA expression, serum TNFα and other related-cytokine levels after intervention; and 2) assess correlations between blood markers and exercise levels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!